Over the past several years, a plethora of new treatments have been approved for the treatment of non–muscle-invasive bladder cancer (NMIBC). In this brief, 17-question survey, developed by Urology Times® Co–Editor-in-Chief Michael S. Cookson, MD, MMHC, the editors of Urology Times are seeking to measure urologists’ treatment patterns and preferences in BCG-unresponsive NMIBC. All responses are confidential and reported in aggregate only.
